JP2002514587A - 生物活性組成物 - Google Patents
生物活性組成物Info
- Publication number
- JP2002514587A JP2002514587A JP2000547960A JP2000547960A JP2002514587A JP 2002514587 A JP2002514587 A JP 2002514587A JP 2000547960 A JP2000547960 A JP 2000547960A JP 2000547960 A JP2000547960 A JP 2000547960A JP 2002514587 A JP2002514587 A JP 2002514587A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- bioactive agent
- agent
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 17
- 239000012867 bioactive agent Substances 0.000 claims abstract description 51
- 239000011159 matrix material Substances 0.000 claims abstract description 41
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- 239000007858 starting material Substances 0.000 claims abstract description 22
- 150000002148 esters Chemical class 0.000 claims abstract description 19
- 229920000728 polyester Polymers 0.000 claims abstract description 19
- 239000007787 solid Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 239000013543 active substance Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 238000005886 esterification reaction Methods 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- 238000012384 transportation and delivery Methods 0.000 claims description 6
- -1 acrylate sugars Chemical class 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 150000002009 diols Chemical class 0.000 claims description 2
- 239000002612 dispersion medium Substances 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000000506 psychotropic effect Effects 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 150000004072 triols Chemical class 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 238000001556 precipitation Methods 0.000 abstract description 10
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 45
- 230000004888 barrier function Effects 0.000 description 18
- 238000013459 approach Methods 0.000 description 13
- 229960002702 piroxicam Drugs 0.000 description 11
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229920000260 silastic Polymers 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002821 anti-nucleating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000005331 crown glasses (windows) Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801704A SE9801704D0 (sv) | 1998-05-14 | 1998-05-14 | Biologically active composition |
| SE9801704-9 | 1998-05-14 | ||
| PCT/SE1999/000823 WO1999058108A1 (fr) | 1998-05-14 | 1999-05-12 | Composition biologiquement active |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002514587A true JP2002514587A (ja) | 2002-05-21 |
| JP2002514587A5 JP2002514587A5 (fr) | 2006-06-29 |
Family
ID=20411318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000547960A Pending JP2002514587A (ja) | 1998-05-14 | 1999-05-12 | 生物活性組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6537576B1 (fr) |
| EP (1) | EP1082102B1 (fr) |
| JP (1) | JP2002514587A (fr) |
| KR (1) | KR100592971B1 (fr) |
| CN (1) | CN1309553A (fr) |
| AT (1) | ATE310500T1 (fr) |
| AU (1) | AU736480B2 (fr) |
| CA (1) | CA2331527C (fr) |
| DE (2) | DE69928524T2 (fr) |
| ES (1) | ES2155048T3 (fr) |
| GR (1) | GR20010300013T1 (fr) |
| HU (1) | HUP0102426A2 (fr) |
| IL (2) | IL139576A0 (fr) |
| NO (1) | NO20005724L (fr) |
| NZ (1) | NZ508073A (fr) |
| PL (1) | PL344051A1 (fr) |
| SE (1) | SE9801704D0 (fr) |
| TR (1) | TR200003589T2 (fr) |
| WO (1) | WO1999058108A1 (fr) |
| ZA (1) | ZA200006474B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064149A1 (fr) * | 2000-02-29 | 2001-09-07 | Jie Zhang | Timbre transdermique pour medicament ameliore |
| AU2007260739A1 (en) | 2006-06-14 | 2007-12-21 | Dr. Reddy's Laboratories Limited | Topical compositions |
| US20080226698A1 (en) * | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
| AU2009302853B2 (en) | 2008-10-06 | 2014-09-11 | Mylan Technologies, Inc. | Amorphous rotigotine transdermal system |
| JP6114841B2 (ja) | 2013-02-28 | 2017-04-12 | ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． | グリコピロレート塩 |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997000670A1 (fr) * | 1995-06-20 | 1997-01-09 | Bioglan Ab | Composition contenant un agent actif dissous dans un vehicule vitrifiant et sa methode de preparation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD217989A1 (de) | 1983-08-09 | 1985-01-30 | Univ Ernst Moritz Arndt | Verfahren zur herstellung einer pharmazeutischen zubereitung |
| US4940701A (en) * | 1984-01-25 | 1990-07-10 | Beecham Group P.L.C. | Topical drug release system |
| AR246186A1 (es) | 1989-11-17 | 1994-07-29 | Beta Pharm Co | Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica. |
| US5906830A (en) * | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
| GB2306885B (en) * | 1995-11-08 | 1999-07-14 | Reckitt & Colmann Prod Ltd | Supersaturated Pharmaceutical Compositions |
-
1998
- 1998-05-14 SE SE9801704A patent/SE9801704D0/xx unknown
-
1999
- 1999-05-12 CN CN99808547A patent/CN1309553A/zh active Pending
- 1999-05-12 DE DE69928524T patent/DE69928524T2/de not_active Expired - Lifetime
- 1999-05-12 EP EP99927061A patent/EP1082102B1/fr not_active Expired - Lifetime
- 1999-05-12 JP JP2000547960A patent/JP2002514587A/ja active Pending
- 1999-05-12 HU HU0102426A patent/HUP0102426A2/hu unknown
- 1999-05-12 CA CA2331527A patent/CA2331527C/fr not_active Expired - Fee Related
- 1999-05-12 PL PL99344051A patent/PL344051A1/xx unknown
- 1999-05-12 ES ES99927061T patent/ES2155048T3/es not_active Expired - Lifetime
- 1999-05-12 AU AU44050/99A patent/AU736480B2/en not_active Ceased
- 1999-05-12 IL IL13957699A patent/IL139576A0/xx active IP Right Grant
- 1999-05-12 WO PCT/SE1999/000823 patent/WO1999058108A1/fr active IP Right Grant
- 1999-05-12 KR KR1020007012708A patent/KR100592971B1/ko not_active IP Right Cessation
- 1999-05-12 NZ NZ508073A patent/NZ508073A/xx not_active IP Right Cessation
- 1999-05-12 AT AT99927061T patent/ATE310500T1/de not_active IP Right Cessation
- 1999-05-12 TR TR2000/03589T patent/TR200003589T2/xx unknown
- 1999-05-12 DE DE1082102T patent/DE1082102T1/de active Pending
- 1999-05-12 US US09/700,176 patent/US6537576B1/en not_active Expired - Lifetime
-
2000
- 2000-11-09 IL IL139576A patent/IL139576A/en not_active IP Right Cessation
- 2000-11-09 ZA ZA200006474A patent/ZA200006474B/xx unknown
- 2000-11-13 NO NO20005724A patent/NO20005724L/no not_active Application Discontinuation
-
2001
- 2001-04-30 GR GR20010300013T patent/GR20010300013T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997000670A1 (fr) * | 1995-06-20 | 1997-01-09 | Bioglan Ab | Composition contenant un agent actif dissous dans un vehicule vitrifiant et sa methode de preparation |
| JPH11508250A (ja) * | 1995-06-20 | 1999-07-21 | ビオグラン・アクチエボラーグ | ガラス形成性担体に溶解した活性物質からなる組成物及びその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL139576A (en) | 2007-07-04 |
| HUP0102426A2 (hu) | 2002-03-28 |
| ATE310500T1 (de) | 2005-12-15 |
| CN1309553A (zh) | 2001-08-22 |
| SE9801704D0 (sv) | 1998-05-14 |
| NZ508073A (en) | 2002-12-20 |
| WO1999058108A1 (fr) | 1999-11-18 |
| DE69928524D1 (de) | 2005-12-29 |
| TR200003589T2 (tr) | 2001-03-21 |
| EP1082102B1 (fr) | 2005-11-23 |
| KR100592971B1 (ko) | 2006-06-23 |
| NO20005724D0 (no) | 2000-11-13 |
| CA2331527A1 (fr) | 1999-11-18 |
| ES2155048T3 (es) | 2006-06-16 |
| GR20010300013T1 (en) | 2001-04-30 |
| DE69928524T2 (de) | 2006-08-10 |
| ES2155048T1 (es) | 2001-05-01 |
| IL139576A0 (en) | 2002-02-10 |
| DE1082102T1 (de) | 2001-09-06 |
| PL344051A1 (en) | 2001-09-24 |
| EP1082102A1 (fr) | 2001-03-14 |
| KR20010052348A (ko) | 2001-06-25 |
| CA2331527C (fr) | 2010-04-13 |
| US6537576B1 (en) | 2003-03-25 |
| NO20005724L (no) | 2001-01-09 |
| AU4405099A (en) | 1999-11-29 |
| ZA200006474B (en) | 2001-09-04 |
| AU736480B2 (en) | 2001-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4884223B2 (ja) | 経皮医薬組成物 | |
| US5093133A (en) | Method for percutaneous delivery of ibuprofen using hydroalcoholic gel | |
| PT1510213E (pt) | Sistemas de melhoramento de penetração e reduzida irritação incluíndo testosterona | |
| JP2794022B2 (ja) | ブナゾシン或いはその塩類含有経皮適用製剤 | |
| WO2000033820A2 (fr) | Systemes noyau-coque nanoparticulaires et leur utilisation dans des preparations pharmaceutiques et cosmetiques | |
| JPS6135166B2 (fr) | ||
| US5795916A (en) | Composition of external preparation | |
| WO1995004551A1 (fr) | Preparation absorbable par voie percutanee | |
| JP2002514587A (ja) | 生物活性組成物 | |
| AU742921B2 (en) | Biologically active composition | |
| GB2306885A (en) | Supersaturated pharmaceutical compositions | |
| MXPA00011082A (en) | Biologically active composition | |
| CZ20004127A3 (cs) | Biologicky aktivní prostředek a způsob jeho přípravy | |
| JPS62215528A (ja) | 経皮投与製剤 | |
| MXPA00011077A (en) | Biologically active composition | |
| Bisht et al. | GEL AS A TOPICAL DRUG DELIVERY SYSTEM: A REVIEW | |
| JPH01207246A (ja) | 外用製剤用基剤組成物及び外用医薬組成物 | |
| CZ20004128A3 (cs) | Biologicky aktivní prostředek a způsob jeho přípravy | |
| KR100294874B1 (ko) | 신규소프트하이드로겔타잎의외용제제및그제조방법 | |
| KR20240085312A (ko) | 바이오틴이 담지된 나노파티클 및 이의 제조 방법, 및 이의 용도 | |
| KR20000013593A (ko) | 피록시캄의 경피투여 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060511 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060511 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090929 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100412 |
|
| RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20100412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100412 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100517 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101012 |